Brief: Athira Pharma Extends Ongoing Open Label Extension Study For Lift-Ad And Act-Ad Clinical Trials Of Fosgonimeton (Ath-1017) For Mild To Moderate Alzheimer’S Disease

LeonaBio

09/05/2022 12:33

May 9 (Reuters) - Athira Pharma Inc  ATHA.O :
    * ATHIRA PHARMA EXTENDS ONGOING OPEN LABEL EXTENSION STUDY
FOR
LIFT-AD AND ACT-AD CLINICAL TRIALS OF FOSGONIMETON (ATH-1017)
FOR MILD TO MODERATE ALZHEIMER’S DISEASE
    * ATHIRA PHARMA INC - STUDY DURATION INCREASED FROM 6 MONTHS
TO 18
MONTHS OF OPEN LABEL TREATMENT WITH FOSGONIMETON

Source text for Eikon:  ID:nGNX8FLhWX 
Further company coverage:  ATHA.O 

 ((Reuters.Briefs@thomsonreuters.com;))